NL-OMON44168已完成不适用
A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment with the Holaira* Lung Denervation System in Patients with Moderate to Severe COPD. - AIRFLOW
Holaira, Inc.0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Diagnosis of COPD with FEV1 30% to 60% and FEV1/FVC <70% (post-bronchodilator);
- •2. mMRC grade * 2 or CAT score * 10 at the time of enrollment
- •3 Positive relative change in FEV1 and/or FVC of >12% and >200 mL following administration of ipratropium bromide during reversibility testing (only phase A);
- •4. Patient *40 and *75 years of age at the time of consent;
- •5. Women of child bearing potential must have a negative pregnancy test (serum or urine) at screening and agree not to become pregnant for the duration of the study;
- •6. Smoking history of at least 10 pack years;
- •7. Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the study;(Negative nicotine test required, unless subject is currently taking smoking cessation medication, patch, gum, etc.)
- •8. Participated in a pulmonary rehabilitation program and/or confirmed to have been engaged or attempted regular physical activity under professional supervision in the past 12 months and agrees to continue or restart regular physical activity for duration of study;
- •9. Current influenza vaccination and/or pneumococcus vaccination consistent with local recommendations and/or policy;
- •10. Patient is a candidate for bronchoscopy in the opinion of the physician or per hospital guidelines;
- •11.The patient is willing, able and agrees to complete all protocol required baseline and follow up testing assessments including taking and abstaining from certain medications (e.g., tiotropium bromide capsules);
- •12.Patient has provided written informed consent using a form that has been reviewed and approved by the Ethics Committee (EC).
排除标准
- •1. Has been <6 weeks (from start of testing) following the resolution of a COPD exacerbation or active lower respiratory infection (e.g. pneumonia); (NOTE: The start of testing may be delayed in order to accommodate this requirement.)
- •2. History of recurrent respiratory infections and/or COPD exacerbations (more than 2 hospitalizations within 1 year of enrollment);
- •3. Prior lung or chest procedure (e.g. lung transplant, LVRS, BLVR, lung implant, metal stent, valves, coils, median sternotomy, bullectomy, segmentectomy or lobectomy, etc);
- •4. Documented history of asthma diagnosed with onset <30 years of age, cystic fibrosis, tuberculosis, paradoxical vocal cord motion, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis or severe interstitial lung disease or active tuberculosis;
- •5.Pre-existing diagnosis of pulmonary hypertension, defined as a sustained elevation of the mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest by right heart catheterization; or estimated by echocardiogram to be greater than 40 mm Hg;
- •6. Pulmonary nodule requiring follow-up or intervention unless proven benign;
- •7. Inability to perform exercise tolerance testing without physical assistance; (Note: normal walking aids allowed (e.g. cane, walker))
- •8. Malignancy treated with radiation or chemotherapy within the last 2 years;
- •9. Failed Cardiac Clearance: defined as myocardial infarction within last 6 months, EKG with evidence of life threatening arrhythmias or acute ischemia, pre-existing documented evidence of an LVEF <45%, stage C or D (ACC/AHA) or Class III or IV (NYHA) congestive heart failure, or any other past or present cardiac findings that make the patient not an acceptable candidate for a bronchoscopic procedure utilizing general anesthesia;
- •10. Patient has an implantable electronic device;
- •11. Patient has a PaO2 *7.3 kPa (55 mm Hg) and/or a PaCO2 >8.0 kPa (60 mm Hg) on room air;
- •12. Uncontrolled diabetes as evidenced by an HbA1C >7%;
- •13. Known coagulopathy;
- •14. Known hypersensitivity to anticholinergic drugs or components;
- •15. Known allergy to medications required for bronchoscopy or general anesthesia (such as lidocaine, atropine, propofol, sevoflurane) that cannot be medically controlled;
- •16. Based on investigator judgment, the patient is unable to stop taking blood thinning medication (with the exception of aspirin) 7 days before and not re-start until 7 days after the study procedure;
- •17. Daily use of >10 mg of prednisone or its equivalent at the time of enrollment;
- •18. Documented history of untreated severe (AHI index >30/hr) obstructive sleep apnea;
- •19. Body Mass Index <18 or >33 male/34 female
- •20. The patient has any disease or condition that might interfere with completion of this study (e.g., life expectancy <3 years);
- •21. Patient is currently enrolled in another clinical trial that has not completed follow-up;
- •22. Screening Chest CT Scan reveals bronchi anatomy cannot be fully treated with available catheter sizes, presence of severe emphysema (as determined by the CT core lab).
- •23. In the opinion of the treating investigator, use of the Holaira System is not technically feasible due to patient anatomy or other clinical finding;
- •24. Previous diagnosis of Alpha 1-antitrypsin deficiency (defined as <0.8 g/l) (Phase A only);
- •25. Clinically relevant bronchiectasis;
- •26. Patients who had abdominal surgical procedures on
研究者
相似试验
进行中（未招募）
不适用
A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-label Current Protease Inhibitor (PI) therapy in HIV-1 Infected, PI Experienced Adults for 2 weeks with Long-Term Evaluation (> 48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected GW640385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, PI Containing RegimeTreatment of HIV-1 infection.EUCTR2005-001150-24-GBGlaxoSmithKline Research & Development Ltd.105
进行中（未招募）
不适用
A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-label Current Protease Inhibitor (PI) therapy in HIV-1 Infected, PI Experienced Adults for 2 weeks with Long-Term Evaluation (> 48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected GW640385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, PI Containing RegimeTreatment of HIV-1 infection.EUCTR2005-001150-24-PTGlaxoSmithKline Research & Development Ltd.105
进行中（未招募）
不适用
A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-label Current Protease Inhibitor Therapy in HIV-1EUCTR2005-001150-24-ITGLAXO SMITHKLINE
进行中（未招募）
不适用
A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-label Current Protease Inhibitor (PI) therapy in HIV-1 Infected, PI Experienced Adults for 2 weeks with Long-Term Evaluation (> 48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected GW640385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, PI Containing RegimeTreatment of HIV-1 infection.EUCTR2005-001150-24-DEGlaxoSmithKline Research & Development Ltd.105
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease.Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF)MedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-005131-40-HUF. Hoffmann-La Roche Ltd177